To evaluate the effectiveness of a prototype antimicrobial blue light (ABL) device in managing MRSA-infected skin wounds in a preclinical swine model, highlighting the significance of MRSA in wound infections.
Key Findings:
ABL treatment reduced MRSA infection by over 99.99% after two treatments (P < .0001).
The device demonstrated significant efficacy against biofilm-associated infections.
No existing devices for treating human cutaneous wounds with ABL are currently registered.
Interpretation:
The ABL device shows promise as a complementary treatment to antibiotics, potentially reducing the need for antibiotic use and mitigating antimicrobial resistance, particularly in biofilm-associated infections.
Limitations:
The study is preclinical and conducted in a swine model, which may not fully predict human responses, particularly in terms of healing and infection dynamics.
Further studies are needed to evaluate long-term effects and safety in humans.
Conclusion:
The ABL device represents a novel approach to managing infected wounds, warranting further development and clinical investigation, particularly in human trials.
by Laisa Bonafim Negri, William Farinelli, Sandeep Korupolu, Ying Wang, Yara Mannaa, Hang Lee, Jie Hui, Pu-Ting Dong, Andrea Slate, Joshua Tam, R Rox Anderson, Seok-Hyun Andy Yun, Jeffrey A Gelfand
